MAIL MAN

[righty]

VIVK news out will slingshot this stock
Mon, December 14, 2009 7:18:08 AMFrom: "[e-mail]" <[e-mail]>Add to Contacts



--------------------------------------------------------------------------------




December 14, 2009











HOME

ABOUT US

DISCLAIMER

CONTACT US


Featured Company News Update






Dear Subscriber,



This morning VIVK announced expansion into Japan for its Vivathermic Vial product line.



As you may recall, the VIVK VivaThermic CryoVial Technology is revolutionary method for recovery of viable cells post-cryopreservation.

http://www.vivakor.com/products/vivathermic-vials



This 5 year EXCLUSIVE distribution agreement with Veritas Corporation of Tokyo equals confirms the worldwide acceptance of this eye popping technology. Veritas is a distribution "King Kong" in Japan and doesn't sign exclusive 5 year agreements with just anybody.



Don't be shocked to see VIVK continue to steamroll ahead with each of their amazing product lines with a continuum of announcements!!









About VIVAKOR








Vivakor, Inc. (“Vivakor,” the “Company,” or “we”) is a transdisciplinary research company that develops products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds. We also provide contract research services for third parties. We have developed numerous products and have filed many patents or provisional patents with the United States Patent and Trademark Office (USPTO). We intend to commercialize such products, after completion of any required regulatory approvals, through one of three methods: a sale of the technology, licensing of the product to a manufacturer or distributor or, in some cases, by manufacturing, marketing and directly selling the products ourselves.

Our business model is to be a research hub focused on areas that have both an identified scientific need and a substantial market opportunity. Our company mission is to advance new ideas to improve the quality of life for individual patients, researchers, clinician or consumer. We believe that the development of substantive technologies and cures for complex human conditions, illnesses and diseases require a sophisticated approach with contribution from many areas of scientific expertise typically requiring a lengthier trajectory to market. Our hub approach is intended to provide the necessary environment of transdisciplinary collaboration and cross-pollination to advance this type of research. Our research is anchored by our relationship with collaborative partners and product-specific commercialization strategies. From the commencement of product conception through development, we target specific commercialization strategies and expect to have collaborative partners or licensing arrangements in place for each of our products before completion. We expect this model to offer several advantages to our shareholders, including a more efficient research and development process and a quicker time to market after completion of development.


For more information about Vivakor, please visit OTCMB Featured Company page: http://www.otcmarketbulls.com/companyDetails.php?compSymbol=VIVK



Latest Company News
Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation


Dec 14, 2009 6:00:00 AM


CORALVILLE, Iowa, Dec. 14 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the launch of its new website promoting its remarkable VivaThermic Vial at www.vivathermic.com. In addition to providing customers with the latest news and developments for its VivaThermic product line, Vivakor developed this site to be a valuable resource for its domestic and international customers, such as the highly respected Veritas Corporation of Tokyo, Japan, which signed an exclusive five year exclusive distribution agreement to distribute Vivakor's VivaThermic products in Japan. Under the terms of the Agreement, Veritas will have exclusive distribution rights to all Vivakor's VivaThermic Division products in Japan, including the recently released VivaThermic SUPER-150 and VivaThermic UTLRA-300 cryovials.



Mr. Shinsaku Iida, President of Veritas Corporation, stated: "As a leading distributor of a biotech products in Japan, including capital equipment, reagents, and kits to support research in the fields of genomics, proteomics, and metabolomics, we believe we are the perfect partner for Vivakor and their VivaThermic product line. In Japan, as in the rest of the world, there is a real need for better sample preparation methods that will allow for the safe, rapid, and reliable sample preservation from a variety of biomaterials. We are very impressed with new Ultra CryoVials, believe that it is the best system available for sample preservation, and believe that we will be very successful in placing the entire cryo-preservation system in the Japanese market as 21 century's gold standard."



Vivakor's CEO, Dr. Tannin Fuja, indicated that, "We are pleased to launch the VivaThermic website that will not only promote domestic distribution but assist our international distributors. We are also pleased to partner with the highly-respected Japanese corporation, Veritas, to distribute our superior VivaThermic products. The Japanese biotechnology industry is one of the leading participants in the global biotech market. Japan, with its family of industry leading biotechnology companies, continues to lead in this increasingly global market."









Disclaimer Release Of Liability: OTCMarketBulls.com is an independent electronic publication, which provides industry data and information on publicly traded companies for the use of our readers. All material herein is information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by OTCMarketBulls.com to be accurate, and should not be considered to be all-inclusive. This profile contains forward-looking statements that involve risks and uncertainties. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward looking statements. Statements in this press release about the companys future expectation! s other than historical facts, are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Act of 1934, as that term is defined in the Private Securities Reform Act of 1995. Investors are cautioned that any information in this communication contains certain such forward-looking statements that involve substantial risks and uncertainties. When used, the words "anticipate," "believe," "estimate," "expect," and similar expressions, as they relate to the company or its management, are intended to identify such forward-looking statements. The company's actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward looking statements. Such "forward-looking statements" are subject to risks and uncertainties set forth from time to time in the companys SEC reports that could cause results to differ materially from those expressed or implied include, but are not limited to, the results of future tests and the availability of funding for additional research and development. This material is for informat ional purposes only and should NOT be construed as an offer or solicitation of an offer to buy or sell any se curities. OTCMarketBulls may liqu i date any securities issued when deemed appropriate to do so. Such liquidation may have a negative impact on the securities being liquidated. OTCMarketBulls is not a licensed broker, broker dealer, market marker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on www.otcmarketbulls.com. OTCMarketBulls and/or its affiliates have received fifty thousand dollars from a third party for advertising. OTCMarketBulls affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise! in value. OTCMarketBulls does not and will not offer any opinion as to when others should sell; each investor must make that decision.




Please Click here to unsubscribe OTC Newsletter.